Your browser doesn't support javascript.
loading
Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
Taverna, Josephine A; Hung, Chia-Nung; DeArmond, Daniel T; Chen, Meizhen; Lin, Chun-Lin; Osmulski, Pawel A; Gaczynska, Maria E; Wang, Chiou-Miin; Lucio, Nicholas D; Chou, Chih-Wei; Chen, Chun-Liang; Nazarullah, Alia; Lampkin, Shellye R; Qiu, Lianqun; Bearss, David J; Warner, Steven; Whatcott, Clifford J; Mouritsen, Lars; Wade, Mark; Weitman, Steven; Mesa, Ruben A; Kirma, Nameer B; Chao, Wei-Ting; Huang, Tim H-M.
Afiliación
  • Taverna JA; Division of Hematology and Oncology, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas.
  • Hung CN; Department of Life Science, Tunghai University, Taichung, Taiwan.
  • DeArmond DT; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas.
  • Chen M; Department of Cardiothoracic Surgery, University of Texas Health Science Center, San Antonio, Texas.
  • Lin CL; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas.
  • Osmulski PA; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas.
  • Gaczynska ME; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas.
  • Wang CM; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas.
  • Lucio ND; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas.
  • Chou CW; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas.
  • Chen CL; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas.
  • Nazarullah A; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas.
  • Lampkin SR; Department of Pathology, University of Texas Health Science Center, San Antonio, Texas.
  • Qiu L; Department of Pathology, University of Texas Health Science Center, San Antonio, Texas.
  • Bearss DJ; Department of Pathology, University of Texas Health Science Center, San Antonio, Texas.
  • Warner S; Tolero Pharmaceuticals, Department of Biomarker and Drug Discovery, Lehi, Utah.
  • Whatcott CJ; Tolero Pharmaceuticals, Department of Biomarker and Drug Discovery, Lehi, Utah.
  • Mouritsen L; Tolero Pharmaceuticals, Department of Biomarker and Drug Discovery, Lehi, Utah.
  • Wade M; Tolero Pharmaceuticals, Department of Biomarker and Drug Discovery, Lehi, Utah.
  • Weitman S; Tolero Pharmaceuticals, Department of Biomarker and Drug Discovery, Lehi, Utah.
  • Mesa RA; Institute for Drug Development, University of Texas Health Science Center, San Antonio, Texas.
  • Kirma NB; Division of Hematology and Oncology, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas.
  • Chao WT; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas.
  • Huang TH; Department of Life Science, Tunghai University, Taichung, Taiwan. huangt3@uthscsa.edu wtchao@thu.edu.tw.
Cancer Res ; 80(7): 1551-1563, 2020 04 01.
Article en En | MEDLINE | ID: mdl-31992541
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogénicas / Proteínas Tirosina Quinasas Receptoras / Inhibidores de Proteínas Quinasas / Janus Quinasa 1 / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Aged80 Idioma: En Revista: Cancer Res Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogénicas / Proteínas Tirosina Quinasas Receptoras / Inhibidores de Proteínas Quinasas / Janus Quinasa 1 / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Aged80 Idioma: En Revista: Cancer Res Año: 2020 Tipo del documento: Article